Last updated: February 23, 2026
What is the Manufactured Drug?
NDC 00069-4220 corresponds to Methylprednisolone Sodium Succinate for Injection, 40 mg/mL, 25 mL vials. It is a corticosteroid used for inflammatory and allergic conditions, often administered in hospitals or clinics.
Market Overview
Manufacturing and Distribution
- Manufacturers: Several companies produce methylprednisolone sodium succinate injection, including Pfizer, Sandoz, and Mylan.
- Distribution: Primarily distributed to hospitals, clinics, and specialty pharmacies. The injectable form accounts for approximately 40% of methylprednisolone sales.
- Market segments: Hospital use dominates, with outpatient clinics and specialty pharmacies accounting for the remainder.
Market Size and Trends
- The global corticosteroid market was valued at approximately $3.5 billion in 2022, with injectable corticosteroids comprising roughly 25%.
- The U.S. corticosteroid market was approximately $1.2 billion in 2022, with methylprednisolone products representing around 35% of this segment.
- Annual growth rate projected at 2-3% over the next five years, driven by increasing demand for inflammation treatment and hospitalizations.
Competitive Landscape
| Product |
Market Share |
Price Range (per vial) |
Key Features |
| Pfizer Methylprednisolone |
~40% |
$35 - $50 |
Proven reliability, broad distribution |
| Sandoz Methylprednisolone |
~25% |
$30 - $45 |
Cost-effective alternative |
| Mylan Methylprednisolone |
~15% |
$28 - $42 |
Generic focus, widespread supply |
| Other (branded generics) |
~20% |
$28 - $50 |
Varies by supplier |
Regulatory Status
- Approved by the FDA, with no recent recalls or major safety alerts.
- Cost varies by supplier and contract negotiations in hospital procurement.
Price Projections
Short-Term (1-2 Years)
- Current average wholesale price (AWP): $40 per vial.
- Projected price range: $38 - $43 per vial.
- Factors influencing prices include generic competition, supply chain costs, and hospital procurement negotiations.
Medium to Long-Term (3-5 Years)
- Anticipated stabilization around $38 - $42 per vial if no major supply disruptions or patent issues.
- Patent expiration for similar drugs has historically led to price drops of 10-15% within 2 years.
- Market shifts favoring biosimilars or alternative formulations could apply downward pressure.
Impact of External Factors
- Supply Chain Disruptions: Global manufacturing constraints could push prices higher temporarily.
- Regulatory Changes: Approval for biosimilars or new formulations can decrease prices by increasing competition.
- Reimbursement Policies: Changes in hospital or insurance reimbursement rates could affect what payers are willing to cover.
Key Market Drivers and Risks
Drivers
- Increasing hospitalizations for acute inflammatory conditions.
- Growing use in emergency and critical care settings.
- Expanding indications for corticosteroids, including COVID-19-related treatments.
Risks
- Entry of biosimilars or stronger generics.
- Changes in healthcare reimbursement policies.
- Price regulation policies by government authorities.
Summary of Price Projections
| Year |
Low Estimate |
High Estimate |
Notes |
| 2023 |
$38 |
$43 |
Stable supply, competitive prices |
| 2024 |
$37 |
$42 |
Slight decrease expected due to generic competition |
| 2025-2027 |
$36 |
$41 |
Market stabilization, potential biosimilar entry |
Conclusions
The injectable methylprednisolone sodium succinate (NDC 00069-4220) remains a steady component of corticosteroid therapy in hospitals. While prices are expected to remain relatively stable, external factors such as biosimilar entry and supply chain dynamics could influence pricing. The market will likely see only minor fluctuations over the next five years unless significant patent or regulatory changes occur.
Key Takeaways
- NDC 00069-4220 is a widely used corticosteroid injection primarily supplied by generic manufacturers.
- Market size is approximately $30-$50 million annually in the U.S.
- Prices are currently around $40 per vial, with slight downward pressure forecasted.
- The growth outlook remains modest, aligned with overall corticosteroid demand.
- External pressures, including biosimilar competition and regulatory shifts, could influence future prices.
FAQs
1. How does biosimilar entry impact methylprednisolone prices?
Biosimilars increase competition, potentially reducing prices by 10-15% over two years.
2. Are hospital procurement practices a significant factor?
Yes. Bulk purchasing agreements and formularies influence negotiated prices significantly.
3. What is the typical price range for similar corticosteroid injectables?
$28 to $50 per vial, depending on manufacturer and hospital contracts.
4. Could shortages affect prices?
Supply disruptions can temporarily increase prices until supply stabilizes.
5. Is future demand driven by new indications?
Yes. Expanding use in COVID-19 and emerging inflammatory conditions could increase demand slightly.
References
[1] IQVIA. (2022). US Pharmaceutical Market Review.
[2] FDA. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
[3] MarketResearch.com. (2023). Global Corticosteroids Market Analysis.
[4] Medi-Span. (2023). Drug Pricing Data.
[5] S&P Global. (2023). Hospital Procurement and Formularies Report.
